LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.06 31.33

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.01

Max

3.11

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+45.16% upside

Dividendes

By Dow Jones

Prochains Résultats

25 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.3M

1.1B

Ouverture précédente

-28.27

Clôture précédente

3.06

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 févr. 2026, 22:36 UTC

Résultats

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 févr. 2026, 22:32 UTC

Résultats

Woodside Energy Fiscal Year Net Profit Falls 24%

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Global Energy Roundup: Market Talk

23 févr. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 févr. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 févr. 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Crescent Capital Partners Owns 53% of ClearView Wealth

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 févr. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 févr. 2026, 23:39 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 févr. 2026, 23:27 UTC

Résultats

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 févr. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 févr. 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 févr. 2026, 22:31 UTC

Résultats

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 févr. 2026, 22:24 UTC

Résultats

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Underlying Ebitda A$700.9 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 févr. 2026, 22:20 UTC

Résultats

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

45.16% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  45.16%

Haut 4.5 USD

Bas 4.5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat